FTC ex­pands PBM in­ves­ti­ga­tion to in­clude re­bate ne­go­tia­tors

The Fed­er­al Trade Com­mis­sion, which this week sued to block Am­gen’s $28 bil­lion buy­out of Hori­zon, is si­mul­ta­ne­ous­ly ex­pand­ing its probe in­to du­bi­ous prac­tices from phar­ma­cy ben­e­fit man­agers by go­ing af­ter two group pur­chas­ing or­ga­ni­za­tions (GPOs) that ne­go­ti­ate drug re­bates on be­half of PBMs.

The com­pul­so­ry or­ders is­sued by the FTC will re­quire Zinc Health Ser­vices, which is the GPO or re­bate ag­gre­ga­tor for CVS Care­mark, and As­cent Health Ser­vices, which is the GPO for PBMs Ex­press Scripts, Prime Ther­a­peu­tics, En­volve Phar­ma­cy So­lu­tions, and Hu­mana Phar­ma­cy So­lu­tions, to pro­vide more in­for­ma­tion and records on their busi­ness prac­tices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER